SC
ABCL icon

Scotia Capital’s AbCellera Biologics ABCL Stock Holding History

Scotia Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Buy
25,082
+8,157
+48% +$39.9K ﹤0.01% 864
2026
Q1 		$59.1K Buy
16,925
+982
+6% +$3.53K ﹤0.01% 896
2025
Q4 		$54.5K Sell
15,943
-10,723
-40% -$47.9K ﹤0.01% 879
2025
Q3 		$134K Sell
26,666
-2,358
-8% -$10.4K ﹤0.01% 866
2025
Q2 		$99.6K Buy
29,024
+12,953
+81% +$32.2K ﹤0.01% 832
2025
Q1 		$35.8K Buy
16,071
+947
+6% +$2.72K ﹤0.01% 829
2024
Q4 		$44.3K Hold
15,124
– – ﹤0.01% 834
2024
Q3 		$39.3K Buy
15,124
+55
+0.4% +$152 ﹤0.01% 819
2024
Q2 		$44.6K Hold
15,069
– – ﹤0.01% 810
2024
Q1 		$68.3K Buy
+15,069
New +$76.9K ﹤0.01% 801
2022
Q1 		– Sell
-13,127
Closed -$188K – 876
2021
Q4 		$188K Sell
13,127
-2,896
-18% -$43.9K ﹤0.01% 817
2021
Q3 		$321K Buy
16,023
+1,757
+12% +$31.1K ﹤0.01% 701
2021
Q2 		$314K Buy
+14,266
New +$393K ﹤0.01% 709

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Scotia Capital's ABCL Position: Q2 2026 in Review

Scotia Capital increased its AbCellera Biologics (ABCL) stake by 48% in Q2 2026, buying an estimated $39.9K and bringing the position to 25,082 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #864.

Scotia Capital first reported a position in ABCL in Q2 2021 and has held it in 13 quarters since. The position peaked at $321K in Q3 2021. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Scotia Capital held 25,082 shares of AbCellera Biologics worth $197K as of Q2 2026.
  • Scotia Capital bought 8,157 AbCellera Biologics shares in Q2 2026, an estimated $39.9K.
  • AbCellera Biologics made up ﹤0.01% of Scotia Capital's portfolio in Q2 2026, its #864 holding.
  • Scotia Capital first reported a position in AbCellera Biologics in Q2 2021 and has held it in 13 quarters since.
  • Scotia Capital's AbCellera Biologics position peaked at $321K in Q3 2021.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.